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Abstract: Objective was to analyze the role of PD-L1 and its relation to demographic, patho-clinical
and outcome parameters in salivary gland carcinoma (SGC) patients. Patients treated for salivary gland
carcinomas between 1994 and 2010 were included. A retrospective chart review for baseline characteris-
tics, pathohistological, clinical and outcome data was performed. Immunohistochemistry for PD-L1 was
performed using tissue microarrays. PD-L1 expression was assessed in tumor cells and tumor-infiltrating
immune cells (TIIC) and statistical analysis with regard to baseline and outcome data was performed.
Expression of PD-L1 (by means ￿1% of the cells with PD-L1 positivity) was present in the salivary gland
carcinoma cells of 17%, in the TIIC of 20% and in both tumor cells and TIIC of 10% the patients. PD-L1
expression in tumor cells and both tumor cells and TIIC was related to tumor grading (p = 0.035 and p
= 0.031, respectively). A trend towards higher grading was also seen for PD-L1 expression in TIICs (p =
0.058). Patients with salivary duct carcinomas and PD-L1 expressing TIICs showed a significantly worse
DFS and OS (p = 0.022 and p = 0.003, respectively), those with both tumor cells and TIIC expressing
PD-L1 a significantly worse DFS (p = 0.030). PD-L1 expression is present in 17% and 20% of salivary
gland carcinoma cells and TIIC. Ten percent of the patient showed a PD-L1 positivity in both tumor
cells and TIIC. This is related to high tumor grading and therefore might be a negative prognostic factor.
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The expression of PD-L1 in salivary 
gland carcinomas
Domenic Vital1, Kristian ikenberg2, Holger Moch2, Matthias Rössle4 & Gerhard F. Huber3
Objective was to analyze the role of PD-L1 and its relation to demographic, patho-clinical and outcome 
parameters in salivary gland carcinoma (SGC) patients. Patients treated for salivary gland carcinomas 
between 1994 and 2010 were included. A retrospective chart review for baseline characteristics, 
pathohistological, clinical and outcome data was performed. Immunohistochemistry for PD-L1 
was performed using tissue microarrays. PD-L1 expression was assessed in tumor cells and tumor-
infiltrating immune cells (TIIC) and statistical analysis with regard to baseline and outcome data was 
performed. Expression of PD-L1 (by means ≥1% of the cells with PD-L1 positivity) was present in the 
salivary gland carcinoma cells of 17%, in the TIIC of 20% and in both tumor cells and TIIC of 10% the 
patients. PD-L1 expression in tumor cells and both tumor cells and TIIC was related to tumor grading 
(p = 0.035 and p = 0.031, respectively). A trend towards higher grading was also seen for PD-L1 
expression in TIICs (p = 0.058). Patients with salivary duct carcinomas and PD-L1 expressing TIICs 
showed a significantly worse DFS and OS (p = 0.022 and p = 0.003, respectively), those with both tumor 
cells and TIIC expressing PD-L1 a significantly worse DFS (p = 0.030). PD-L1 expression is present in 17% 
and 20% of salivary gland carcinoma cells and TIIC. Ten percent of the patient showed a PD-L1 positivity 
in both tumor cells and TIIC. This is related to high tumor grading and therefore might be a negative 
prognostic factor.
Salivary gland carcinoma (SGC) is a rare disease with an incidence of 25–30 per one million individuals, account-
ing for about 0.5% of all malignancies and 5% of all head and neck cancers1,2. Regardless of its histological subtype, 
curative treatment consists of a surgical resection with or without postoperative adjuvant radiation therapy1,3,4, 
although adjuvant treatment options like (chemo)radiation do not have a detectable impact on survival in highly 
aggressive subtypes like salivary duct carcinomas5. There is also no standard treatment of proven efficacy for 
patients with unresectable primaries/recurrences or patients with distant metastasis1. The benefit of chemothera-
pies like combinations of cisplatin, doxorubicin and cyclophosphamide was reported to be minimal with a prog-
nosis that remains poor1,6–8.
Immunotherapies have shown remarkable success in various entities not limited to non-small cell lung cancer 
and malignant melanoma. All these therapies share a similar mode of action directing the body’s own immune 
system to dispose tumor cells9,10. Although the immune system is one of the major defense elements in antitu-
mor response, tumor cells derive from the patient’s own cells and therefore maintain many natural autoimmune 
defense mechanisms that can prevent tumor immune destruction11. The programmed death (PD)-1/programmed 
death ligand 1 (PD-L1) pathway is one of these mechanisms to elude antitumor immune response, by which 
expansion and activity of cytotoxic T cells is suppressed by binding of the tumor cell’s PD-L1 on the PD-1 recep-
tor on tumor-specific T cells1,12,13. A targeted immune therapy with PD-1/PD-L1 inhibitors (e.g. pembrolizumab, 
atezolizumab) can disrupt these pathways and enhance the immune system’s antitumor activity10.
So far, not much is known about the role of PD-L1 in SGC. Nevertheless, it often affects younger patients 
and efficacy of chemotherapeutic agents is limited as mentioned above, why it would be of advantage to identify 
factors predicting outcome with regard to a patient-tailored treatment. Up to present, there were only a few stud-
ies analyzing the role of PD-L1 in SGC, considering the immune profiling of PD-L1 and –L2 in adenoid-cystic 
carcinomas (ACC) or examining the correlation between PD-L1 expression and clinic-pathologic behavior of 
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SGC1,6,14. Therefore, objective of our study was to analyze the role of PD-L1 and its relation to demographic, 
patho-clinical and outcome parameters in our cohort of patients with SGC.
Materials and Methods
Patients. The study protocol was approved by the ethics committee of the local authority (Kantonale 
Ethikkommission Zürich (KEK); KEK-ZH-Nr. 2010-0206/0). All experiments and analyses were performed in 
accordance with the relevant guidelines and regulations. Informed consent was obtained. Patient with salivary 
gland carcinomas, who underwent treatment between January 1st, 1994 and December 31st, 2010 (17 years) were 
eligible to be included in this study. The same cohort was used in a previous study focusing on the expression 
of cancer testis antigens in salivary gland carcinomas15. Patients with incomplete data sets or insufficient tissue 
quality or quantity were excluded. Retrospective chart review focused on age at initial diagnosis, sex, tumor entity 
and localization, TNM classification (UICC, 7th ed.), tumor grading, resection margins, extranodal extension of 
lymph node metastasis, perineural invasion, blood and lymphatic vessel invasion, recurrence and survival. Given 
that there is no universally used grading system for the different SGC entities, the grading system according to 
Brandwein et al.16 was used for mucoepidermoid carcinoma (MEC) and the grading system according to Szanto 
et al.17 for acinic cell carcinoma (AcCC). Grading of all the other SGC entities was bases on similarity to normal 
tissue of origin, grade of pleomorphism/anaplasia, vascular and perineural invasion and mitotic activity.
All patients underwent resection of their SGC, frequently treated with postoperative radiation therapy. 
Radiation therapy was indicated in case of large primaries with infiltration of surrounding tissues, high-grade 
histology, perineural or lymphovascular invasion, close or positive resection margins, multiple lymph node 
metastasis or lymph node metastasis with extranodal extension. None of the patients underwent treatment with 
PD-1/PD-L1 inhibitors.
Disease free survival (DFS) is the period of time without evidence of disease (i.e. persistence, recurrence or 
metastasis) after primary treatment. Disease-specific survival (DSS) and overall survival (OS) were defined as the 
duration after primary treatment to death due to SGC or any other reason, respectively. Oncologic follow-up was 
performed at the Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Zurich. 
It consisted of clinical examinations and routine use of ultrasonography as well as cross-sectional imaging (MRI 
and/or PET-CT). Minimal oncologic standard surveillance time in SGC patients with salivary gland carcinomas 
is 10 years.
Tissue microarray construction/immunohistochemistry. To perform immunohistochemistry, sec-
tions of a tissue microarray (TMA), which has been previously described, were used15. Briefly, two core biopsies 
(diameter, 0.6 mm; length, 3–4 mm) from a morphologically representative area of interest of the paraffin ‘donor’ 
blocks were precisely arrayed into a new ‘recipient’ paraffin block using a stereomicroscope and the Beecher 
TMA instrument (Beecher Instruments, Sun Prairie, WI)18. From these (“recipient”) TMA paraffin blocks, 3.0 μm 
sections were freshly cut and used for further immunohistochemistry. The staining procedure was conducted 
according to the manufacturer’s instructions on an automated staining system (Leica Bond-III, Leica Biosystems, 
Wetzlar Germany). Briefly for PD-L1: Pretreatment Buffer H1, rabbit monoclonal anti PD-L1 (SP142) antibody 
(Spring Bioscience, Pleasanton, CA, USA)19. A tonsillectomy specimen served as positive control. A dilution of 
1:100 resulted in a strong and distinct membranous staining pattern without unspecific background signal in pos-
itive controls (tonsil, Fig. 1). Staining intensity was analyzed using the percentage of positive cells (PP). Positivity 
for PD-L1 was defined as any unequivocal membranous staining of at least 1% of the tumor cells or the tumor 
infiltrating immune cells (TIIC)1,20. Multiple core’s PP were averaged and rounded to the nearest whole number. 
Two different authors (K.I. and D.V.), both blinded for the patient’s data, analyzed the percentage of positive 
tumor cells and TIIC.
Statistics. Data was analyzed using descriptive statistics. Analysis of variance (ANOVA) and chi-square 
tests were performed to analyze baseline characteristics. The relationship between the PD-L1 expression 
and the clinico-pathologic variables such as TNM classification or tumor grading (which were used in its 
non-dichotomized form) were correlated using cross tabulation and chi square test. DFS, DSS and OS were com-
pared with Kaplan-Meier survival analyses and log rank tests. SPSS statistics (IBM Corp; Armonk, NY), version 
24, was used to assist with statistical analysis. A p-value < 0.05 was considered statistically significant.
Results
Retrospective chart review enabled identification of 167 patients with malignant salivary gland tumors and a 
mean age of 57.2 ± 18.9 years (mean ± standard deviation, range 8–95 years). Eighty-three patients were women 
(49.7%), 84 men (50.3%). Tumor localization was in the parotid gland in 118 cases (70.6%), in the subman-
dibular gland in 18 cases (10.8%), in the sublingual gland in one case (0.6%) and in other/accessory salivary 
glands in 30 patients (18.0%). Overall mean estimated DFS was 121.2 months (95% CI 105.5–137.0 months), DSS 
225.7 months (95% CI 208.5–242.9 months) and OS 174.0 months (95% CI 152.4–195.5 months). Patients were 
followed-up over a mean period of 68.9 months (95% confidence interval (CI) 60.2–77.7 months, range 0–271 
months).
As expected the well-established prognostic factors TNM classification, tumor grading, perineural, vascular 
and lympho-vascular invasion had a highly significant impact on DFS, DSS and OS (all p < 0.018).
Baseline characteristics of the patients among PD-L1 positivity and negativity are depicted in Table 1. Of the 
167 patients, 28 (16.8%) showed positivity of PD-L1 in tumor cells and 34 (20.4%) in TIIC (Fig. 2). Seventeen 
patients (10.2%) demonstrated positivity for PD-L1 in both in both tumor cells and TIIC (Table 2). Patients with 
PD-L1 positive tumor cells and both tumor cells and TIIC positive for PD-L1 showed a higher histologic tumor 
grade than their negative counterparts (p = 0.035 and p = 0.031, respectively), whereas there was no further 
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correlation of PD-L1 expression with baseline characteristics. A trend towards a higher grading was present in 
TIIC PD-L1 positive tumors (p = 0.085). The four different groups of patients with PD-L1 positivity or negativity 
in tumor cells and/or TIIC (i.e. both tumor and TIIC positive, tumor positive/TIIC negative, tumor negative/TIIC 
positive, both tumor and TIIC negative) did not show any significant difference with regard to DFS, DSS or OS. 
Also, PD-L1 expression did not influence patient’s outcome if stratified by histologic tumor grading. The extent of 
immune infiltrate in relation to PD-L1 positivity is given in Table 3. In patients with PD-L1 positive TIIC, extent 
of immune infiltrate was significantly higher (p < 0.001).
PD-L1 expression in tumor cells and TIIC of to the various tumor entities are depicted in Table 4. Outcome 
analysis with regard to tumor subtype showed a worse DFS (Fig. 3) and OS (Fig. 4) in patients with salivary duct 
carcinoma and PD-L1 expressing TIIC (p = 0.022 and p = 0.003, respectively). This was also true with regard to 
DFS in patients with both SDC cells and TIIC being positive for PD-L1 (p = 0.030, Fig. 5). Due to the small size 
of the sub-cohort of patients with salivary duct carcinoma (n = 10), a multivariate analysis was not performed. 
All other subtypes of SGC did not show a relation between PD-L1 expression in tumor cells and/or TIIC and 
outcome.
Discussion
Our retrospective analysis of PD-L1 expression in salivary gland carcinoma cells and in its tumor infiltrating 
immune cells reports the following major findings:
•	 Expression of PD-L1 (by means ≥1% of the cells with PD-L1 positivity) was present in the salivary gland car-
cinoma cells of 17% and in the TIIC of 20% of the patients. Ten percent of the patients demonstrated PD-L1 
positivity for both tumor cells and TIIC.
•	 PD-L1 expression in tumor cells and both tumor cells and TIIC was related to a higher tumor grading 
(p = 0.035 and p = 0.030, respectively). A trend towards higher grading was also seen for PD-L1 expression 
in TIICs (p = 0.058).
•	 Patients with salivary duct carcinomas and PD-L1 expressing TIICs showed a significantly worse DFS and OS 
than their PD-L1 negative counterparts (p = 0.022 and p = 0.003, respectively), those with both SDC cells and 
TIIC expressing PD-L1 a significantly worse DFS (p = 0.030).
There is scarce literature on the role of PD-L1 in salivary gland carcinomas and only few other studies analyzing 
prognostic relevance of PD-L1 expression in different types of salivary gland carcinomas1,6,21–23: Mukaigawa et al. 
used the same threshold of ≥1% for PD-L1 positivity and demonstrated PD-L1 expression in a slightly higher 
fraction (23%) of the patient’s tumor cells and a moderately lower rate (13%) of the patient’s tumor-infiltrating 
mononuclear cells1. Harada et al. used a threshold of ≥5% for PD-L1 positivity and detected PD-L1 expression 
Figure 1. Tonsil tissue stained for PD-L1 demonstrating the quality of the applied staining protocol with clearly 
negative superficial squamous epithelium (A) and strong diffuse staining in reticular crypt epithelial cells (B), 
consistent with the manufactures specifications.
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in 51.1% of the patients with salivary gland carcinomas22. Other groups, which analyzed the immunoprofile of 
adenoid-cystic carcinoma, did not find any expression of PD-L16 or PD-1 positive SGC infiltrating T cells23. In 
our data, PD-L1 positivity of TIIC was furthermore associated with more extensive immune infiltrate. Consistent 
with the findings of Mukaigawa et al.1, PD-L1 expression in tumor cells and TIIC was associated with higher his-
tological grading of SGC. However, a correlation with AJCC/UICC stage as reported by Harada et al. for membra-
nous PD-L1 positivity22 or a correlation with age, sex, tumor localization, T and N stage as found by Mukaigawa 
et al.1 could not be confirmed with our data.
There is an ongoing debate about the prognostic role of PD-L1 (i.e. the prognostic implication of PD-L1 
expression apart from the treatment with PD-1/PD-L1 blockers) with both favorable and unfavorable outcomes 
being reported in various malignancies24–28. Most of these authors conclude a negative impact of PD-L1 on out-
come, which seems, looking to the data of Mukaigawa et al.1 and Harada et al.22, also to be true for salivary 
gland carcinomas. This effect is explained by its role as an immunosuppressive molecule, which interacts with the 
PD-1 receptor and leads to tumor protection and immunotolerance29–31. Indeed, the link between PD-L1 expres-
sion in both tumor and immune cells can roughly be explained by interferon gamma, which is produced by the 
tumor infiltrating immune cells and is one of the molecular mechanisms inducing PD-L1 expression25,32,33. The 
PD-L1 in tumor cells PD-L1 in tumor-infiltrating immune cells
PD-L1 in tumor and tumor-infiltrating immune 
cells
positive (n = 28, 
16.8%)




positive (n = 34, 
20.4%)










Age 61.5 ± 22.7 years 56.4 ± 18.1 years 0.269 63.1 ± 20.6 years 55.7 ± 18.3 years 0.063 64.5 ± 24.7 years 56.4 ± 18.1 years 0.208
Gender (F/M) 15/13 (53.6/46.4%) 68/71 (48.9/51.1%) 0.653 16/18 (47.1/52.9%) 67/66 (50.4/49.6%) 0.730 9/8 (52.9/47.1%) 74/76 (49.3/51.7%) 0.804
T classification 0.178 0.714 0.376
   T1 3 (10.7%) 32 (23.0%) 7 (20.6%) 28 (21.0%) 2 (11.8%) 33 (22.0%)
   T2 12 (42.9%) 29 (20.9%) 12 (35.3%) 29 (21.8%) 8 (47.1%) 33 (22.0%)
   T3 8 (28.6%) 33 (23.7%) 11 (32.4%) 30 (22.6%) 4 (23.5%) 37 (24.7%)
   T4a 3 (10.7%) 17 (12.2%) 3 (8.8%) 17 (12.8%) 3 (17.6%) 17 (11.3%)
   T4b 0 3 (2.2%) 1 (2.9%) 2 (1.5%) 0 3 (2.0%)
   Tx 2 (7.1%) 25 (18.0%) 0 27 (20.3%) 0 27 (18.0%)
N classification 0.894 0.723 0.681
   N0 11 (39.3%) 53 (38.1%) 14 (41.2%) 50 (37.6%) 6 (35.3%) 58 (38.6%)
   N1 1 (3.6%) 6 (4.3%) 2 (5.9%) 5 (3.8%) 1 (5.9%) 6 (4.0%)
   N2a 2 (7.1%) 6 (4.3%) 3 (8.9%) 5 (3.8%) 1 (5.9%) 7 (4.7%)
   N2b 6 (21.4%) 21 (15.2%) 8 (23.5%) 19 (14.2%) 5 (29.4%) 22 (14.7%)
   Nx 8 (28.6%) 53 (38.1%) 7 (20.5%) 54 (40.6%) 4 (23.5%) 57 (38.0%)
M classification 0.073 0.904 0.543
   M0 18 (64.3%) 111 (79.9%) 26 (76.5%) 103 (77.4%) 12 (70.6%) 117 (78.0%)
   M1 10 (35.7%) 28 (20.1%) 8 (23.5%) 30 (22.6%) 5 (29.4%) 33 (22.0%)
   Mx 0 0 0 0 0 0
Grading 0.035* 0.058 0.031*
   G1 6 (21.4%) 56 (40.3%) 11 (32.4%) 51 (38.3%) 2 (11.8%) 60 (40.0%)
   G2 4 (14.3%) 29 (20.9%) 3 (8.8%) 30 (22.6%) 3 (17.6%) 30 (20.0%)
   G3 18 (64.3%) 52 (37.4%) 20 (58.8%) 50 (37.6%) 12 (70.6%) 58 (38.7%)
   Gx 0 2 (1.4%) 0 2 (1.5%) 0 2 (1.3%)
Perineural invasvion 0.096 0.054 0.305
   Pn0 18 (64.3%) 63 (45.3%) 22 (64.7%) 59 (44.3%) 11 (64.7%) 70 (46.7%)
   Pn1 10 (35.7%) 71 (51.1%) 12 (35.3%) 69 (51.9%) 6 (25.3%) 75 (50.0%)
   Pnx 0 5 (3.6%) 0 5 (3.8%) 0 5 (3.3%)
Lymphatic vessel 
invasion 0.515 0.230 0.404
   L0 19 (67.9%) 99 (71.2%) 22 (64.7%) 96 (72.2%) 11 (64.7%) 107 (71.4%)
   L1 9 (32.1%) 35 (25.2%) 12 (35.3%) 32 (24.0%) 6 (35.3%) 38 (25.3%)
   Lx 0 5 (3.6%) 0 5 (3.8%) 0 5 (3.3%)
Blood vessel invasion 0.056 0.891 1.000
   V0 22 (78.6%) 122 (87.8%) 30 (88.2%) 114 (85.7%) 15 (88.2%) 129 (86.0%)
   V1 6 (21.4%) 12 (8.6%) 4 (11.8%) 14 (10.5%) 2 (11.8%) 16 (10.7%)
   Vx 0 5 (3.6%) 0 5 (3.8%) 0 5 (3.3%)
Table 1. Characteristics of patients of with salivary gland carcinomas (n = 167) with respect to PD-L1 
expression in tumor cells and tumor-infiltrating immune cells. Chi-square test: A p-value < 0.05 is considered 
significant.
5Scientific RepoRtS |         (2019) 9:12724  | https://doi.org/10.1038/s41598-019-49215-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
prognostic relevance of PD-L1 in our study is limited to patients with salivary duct carcinomas, demonstrating an 
adverse effect on outcome in patient with PD-L1 positivity of TIIC.
Salivary duct carcinoma (SDC) is a relatively rare, highly aggressive subtype of SGC, which most likely arises 
from the ductal epithelium and accounts for about 1–3% of all salivary gland malignancies5,34–36. It has one of the 
Figure 2. Representative immunohistochemical staining of salivary gland carcinoma demonstrating 
immunoreactivity in for PD-L1 in tumor-infiltrating immune cells ((B) corresponding H&E staining (A)) 
and in tumor cells ((D) corresponding H&E staining (C)). (A,B and C,D) are two different patients. Scale bar 







PD-L1 negative (n = 133) 122 (73.0%) 11 (6.6%)
PD-L1 positive (n = 34) 17 (10.2%) 17 (10.2%)
Table 2. PD-L1 positivity in tumor cells versus tumor-infiltrating immune cells of different salivary gland 








Intensity of immune infiltrate
0 (n = 6) 0 6 (54,5%) 0
+ (n = 14) 2 (11.8%) 3 (27.3%) 9 (53.0%)
++ (n = 19) 12 (70.6%) 2 (18.2%) 5 (29.4%)
+++ (n = 6) 3 (17..6%) 0 3 (17.6%)
Table 3. Extent of immune infiltrate versus PD-L1 positivity in tumor cells and tumor-infiltrating immune cells 
of different salivary gland carcinomas (n = 167).
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worst outcomes within the group of SGC. Patients with SDC show rapid progression of disease and a high inci-
dence of metastasis (distant metastatic disease in 40–70%), which leads to tumor-related death within 3 years in 
the majority of the patients37–39. Due to its very low incidence, literature is limited to small retrospective studies 
and the optimal treatment remains still unclear, especially given the fact that current adjuvant treatments do 
not have a detectable impact on survival and the effect of chemotherapies for unresectable or metastatic tumors 
remains minimal1,5–8.
Looking at the paucity of literature on SDC, it is difficult to discuss our findings by reviewing of the con-
temporary literature. To our knowledge, there is only one article considering PD-L1 receptor expression as a 
prognostic factor of SDC, which studied 67 patients with SDC or SDC ex pleomorphic adenoma. However, the 
authors Haderlein et al. failed to demonstrate a significant relationship between PD-L1 receptor expression and 
outcome of patients with SDC21. A more recent study by Sato et al. analyzed a small collective of 12 patients with 
SDC and found an unfavorable prognosis in patients with PD-L1 positive tumor cells40. Invasive ductal carcinoma 
of the breast, furthermore, resembles SDC and shows similar immunohistochemical staining patterns37,41,42. It is 
well known that PD-L1 expression in ductal carcinoma of the breast is correlated with high-risk features such 
as tumor grading and therefore could be an indicator of advanced stage and poor prognosis30,43,44. The adverse 
effect of PD-L1 expression in TIIC on outcome in the context of invasive ductal breast cancer can be explained by 
the following effects: An inhibition of T lymphocyte clonal expansion either by reverse signaling processes or by 





Mucoepidermoid carcinoma (n = 36) 9 (25%) 13 (36%)
Adenoic cystic carcinoma (n = 36) 3 (8%) 1 (3%)
Acinic cell carcinoma (n = 30) 4 (13%) 6 (20%)
Adenocarcinoma NOS (n = 12) 2 (17%) 4 (33%)
Epithelial-myoepithelial carcinoma (n = 11) 0 2 (2%)
Salivary duct carcinoma (n = 10) 3 (30%) 4 (40%)
Carcinoma ex pleomorphic adenoma (n = 10) 1 (10%) 0
Polymorphous low grade adenocarcinoma (n = 7) 1 (14%) 0
Basal cell adenocarcinoma (n = 3) 1 (33%) 0
Squamous cell carcinoma (n = 2) 1 (50%) 1 (50%)
Small cell carcinoma (n = 2) 1 (50%) 1 (50%)
Large cell carcinoma (n = 1) 1 (100%) 1 (100%)
Lymphoepithelial carcinoma (n = 1) 1 (100%) 1 (100%)
All carcinomas (n = 167) 28 (17%) 34 (20%)
Table 4. PD-L1 positivity in tumor cells and tumor-infiltrating immune cells of different salivary gland 
carcinomas (n = 167). Patients with oncocytic carcinoma (n = 2), myoepithelial carcinoma (n = 2), 
cystadenocarcinoma (n = 1) and carcinosarcoma (n = 1) did not show any PD-L1 positivity in either tumor cells 
or tumor-infiltrating immune cells.
Figure 3. Disease-free survival of tumor infiltrating immune cell (TIIC) PD-L1 positive and negative patients 
with salivary duct carcinoma. The statistical difference is significant (p = 0.022).
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Our study has several limitations: It is a retrospective study on a robust number of SGCs, which consists of 
several different tumor entities. Consequently, the subgroups of the different entities are small. However, the 
statistical findings in the rare, but clinically relevant subgroup of SDC are significant. These findings merit evalu-
ation in more detailed studies with larger numbers of SDC in a multicenter setting, which might be applicable to 
future studies on the usefulness of treatment with PD-1/PD-L1 inhibitors in SGC, or SDC in particular.
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